07:47 AM EDT, 07/30/2024 (MT Newswires) -- Incyte ( INCY ) reported a Q2 adjusted loss Tuesday of $1.82 per diluted share, compared with adjusted earnings of $0.99 a year earlier.

Analysts surveyed by Capital IQ expected adjusted EPS of $1.11.

Revenue for the quarter ended June 30 was $1.04 billion, compared with $954.6 million a year earlier.

Analysts surveyed by Capital IQ expected $1.01 billion.

For full-year 2024, the company said it now expects net product revenue for its drug Jakafi to be between $2.71 billion and $2.75 billion, compared with previous guidance of $2.69 billion to $2.75 billion.

Price: 69.04, Change: +0.45, Percent Change: +0.66